Hepatology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Hepatology Search

Hepatology

Hepatology

Home News Diseases Conferences Special Reports

Sodium thiosulfate may prevent cisplatin-induced hearing loss

Roshini Claire Anthony, Yesterday

Administering sodium thiosulfate 6 hours after cisplatin therapy almost halved the incidence of hearing loss in children with hepatoblastoma, according to results of the phase III SIOPEL 6* trial.

Warfarin use after LGIB-related hospitalization does not increase risk of mortality

02 Jul 2018

Resumption of warfarin at discharge following hospitalization for lower gastrointestinal bleeding (LGIB) is not associated with either 90-day or 6-month mortality, reports a study, adding that death in LGIB is primarily caused by age and comorbidities.

Surgical resection superior to radiofrequency ablation for small perivascular HCC

22 Jun 2018

Surgical resection (SR) as a first-line treatment for small perivascular hepatocellular carcinoma (HCC) provides better long-term tumour control than radiofrequency ablation (RFA), a recent study has shown.

Bezafibrate + ursodeoxycholic acid suitable as second-line treatment for primary biliary cholangitis

Roshini Claire Anthony, 20 Jun 2018

The addition of bezafibrate to ursodeoxycholic acid improves biochemical responses over ursodeoxycholic acid alone in patients with primary biliary cholangitis, according to results of the BEZURSO* trial.

Greater plasma pro-NT levels identify NAFLD in adults

Stephen Padilla, 14 Jun 2018

Increased levels of plasma proneurotensin (pro-NT) can predict the presence or severity of nonalcoholic fatty liver disease (NAFLD) in adults, a recent study has shown. Moreover, NT may specifically promote hepatic fat accumulation in dysmetabolic individuals through mechanisms possibly related to increased insulin resistance.

Extending survival with sorafenib in locally advanced hepatocellular carcinoma

04 Dec 2017

Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.

The role of direct-acting antivirals in the new era of hepatitis C treatment

14 Dec 2016

At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.

Case studies: Hepatorenal syndrome

01 Dec 2016

An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.

Treatment of alcoholic hepatitis – Role of S-adenosyl-L-methionine (SAMe)

09 Nov 2016

At a recent Abbott-sponsored satellite symposium held during the GUT Congress 2016 in Kuala Lumpur, an expert from India presented on the management of alcoholic liver disease, and illustrated the role of SAMe as a complementary therapy.

Excerpts from the EXPERT Program Module 3: “Cardiovascular and Fatty Liver Diseases”

03 Sep 2015

Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors.

Cabozantinib shows promising outcomes in advanced HCC

Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

KEYNOTE-224: Durable responses, positive PFS, OS with pembrolizumab in advanced HCC

Roshini Claire Anthony, 19 Feb 2018

Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.

Noninvasive assessment of portal hypertension shows promise

Jackey Suen, 24 Oct 2017

Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.

Serum microRNA signature a biomarker of HBV infection status

Naomi Rodrig, 03 Oct 2017

An index of three liver-specific microRNAs (the MiR-B Index) could serve as a biomarker of spontaneous or treatment-induced transition from active to inactive chronic hepatitis B virus (HBV) infection, facilitating disease monitoring and testing of new antivirals, according to Dr Mauricia Brunetto from the University of Pisa, Italy, who spoke recently at the Asian Pacific Digestive Week (APDW) 2017 in Hong Kong.

New test facilitates diagnosis of idiosyncratic drug-induced liver injury

Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!